Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954445 | 0.90 | KMT2A (0.45) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL5955372 | 0.90 | KMT2A (0.45) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL5955048 | 0.88 | MEN1 (0.47) | MEN1KMT2ATSHRNR1H3SOAT1 | |
| SCHEMBL5955343 | 0.86 | ABCB1 (0.47) | LTA4HMEN1KMT2ATSHRMAPT | |
| SCHEMBL5954469 | 0.86 | ABCB1 (0.47) | LTA4HMEN1KMT2ATSHRMAPT | |
| SCHEMBL5954448 | 0.85 | SMO (0.56) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL5955334 | 0.82 | NPC1 (0.47) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL5955227 | 0.82 | NPC1 (0.47) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL5955264 | 0.81 | KMT2A (0.43) | MEN1KMT2AMAPTALDH1A1SMO | |
| SCHEMBL5955006 | 0.81 | MGLL (0.50) | MEN1KMT2AMAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LABORATOIRES FOURNIER S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
| EP-1546111-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031160-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LIPC, CYP4F2, SLC5A2 | LTA4H 141/4885MEN1 3372/4885KMT2A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.